Please wait a minute...
European Journal of Gynaecological Oncology  2019, Vol. 40 Issue (5): 846-848    DOI: 10.12892/ejgo4852.2019
Original Research Previous articles | Next articles
Loss of 5-hydroxymethylcytosine (5-hmC) expression in endometrioid type endometrial carcinoma
H. Ibrahim1, K. Dresser1, K. M. Cornejo1, *()
1Department of Pathology, University of Massachusetts Medical School, UMass Memorial Medical Center, worcester, MA, USA
Download:  PDF(718KB)  ( 133 ) Full text   ( 4 )
Export:  BibTeX | EndNote (RIS)      
Abstract  

Objectives: Epigenetic alterations such as DNA methylation are important in cancer development. Recently, the epigenetic marker 5-hydroxymethylcytosine (5-hmC) has been shown to be reduced in a variety of cancers and involved in the process of malignant transformation. The expression of 5-hmC in proliferative endometrium and endometrial carcinoma has not been well elucidated. The aim of this study was to investigate 5-hmC protein expression in proliferative endometrium (PE) and endometrioid type endometrial carcinoma (ETEC). Materials and Methods: The authors examined the expression of 5-hmC by immunohistochemistry in a total of 60 cases comprised of 29 PE and 31 ETEC. The percentage of nuclear staining was estimated for each case as: 0-25%, 26-50%, and > 50% loss. Endometrial stroma was used as a positive control for the 5-hmC staining. Results: Among the 29 PE cases, 28 (97%) had strong and diffuse staining with minimal to no loss of 5-hmC expression (≤ 25% of the cells). A loss of 5-hmC staining was observed in > 25% of the cells in 25 of 31 (81%) ETEC cases, of which 16 (52%) of these cases displayed a loss in > 50% of the tumor cells. The loss of 5-hmC expression was significantly increased in ETEC cases in comparison to the PE cases (p < 0.0001) by Fishers exact test. Conclusions: This study demonstrates that 5-hmC expression is significantly reduced in ETEC compared with PE. These findings suggest that the loss of 5-hmC is an epigenetic event in ETEC and may play a role in its development and progression.

Key words:  5-hmC      5-hydroxymethylcytosine      Immunohistochemistry      Endometrium      Endometrial carcinoma     
Published:  10 October 2019     
*Corresponding Author(s):  K. M. CORNEJO     E-mail:  Kcornejo@partners.org

Cite this article: 

H. Ibrahim, K. Dresser, K. M. Cornejo. Loss of 5-hydroxymethylcytosine (5-hmC) expression in endometrioid type endometrial carcinoma. European Journal of Gynaecological Oncology, 2019, 40(5): 846-848.

URL: 

https://ejgo.imrpress.com/EN/10.12892/ejgo4852.2019     OR     https://ejgo.imrpress.com/EN/Y2019/V40/I5/846

[1] Jaudah Al-Maghrabi, Haneen Al-Maghrabi. SIRT1 is overexpressed in endometrial adenocarcinoma: a tissue microarray analysis[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 699-704.
[2] Wook Youn Kim, Shin Hee Seo, Seung-Hyuk Shim, Jin Hee Park, Hyung Kyu Park, Kyeong A So, Tae Jin Kim, Sun Joo Lee. Correlation of immunohistochemistry and silver in situ hybridization for the assessment of c-MET in uterine cervical cancer patients treated with radical hysterectomy[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 745-752.
[3] Hyang Sook Jeong, Yuki Gen, Hui Ryun Joo, Ji Geun Yoo, Seung Geun Yeo, Dong Choon Park. Mesonephric-like carcinoma of the uterine corpus: A case report and literature review[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 664-667.
[4] Soo-Young Lee, Dae-Hyung Lee. Perivascular epithelioid cell tumor arising in the left parametrium: a case report[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 657-660.
[5] Marcin Jedryka, Agnieszka Chrobak, Anna Chelmonska-Soyta, Daria Fijalkowska, Rafal Matkowski. Decreased expression of estrogen receptors alpha and beta in peripheral blood lymphocytes from the endometrial cancer patients and women with endometriosis[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 375-379.
[6] T. Sakamoto, M. Miyamoto, T. Kono, H. Tsuada, H. Matsuura, T. Aoyama, M. Takano, K. Furuya. Endometrial dedifferentiated carcinoma: a case report. Pathological review at a single institution and systematic review of published literature[J]. European Journal of Gynaecological Oncology, 2020, 41(2): 163-166.
[7] H. Cokmez, A. Yilmaz. Concordance of preoperative and postoperative histological grades in endometrioid type endometrial cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(2): 208-213.
[8] Sung-Im Do, Hee-Chul Shin, Hee Sung Kim. Clinical significance of MET receptor protein and mRNA expression in invasive breast cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(2): 240-245.
[9] M. Pakiž, A. Dovnik, B. Crnobrnja, P. Zola. Increased incidence of advanced stage endometrial cancer: a retrospective analysis of different clinical approaches and tumour biology[J]. European Journal of Gynaecological Oncology, 2020, 41(2): 246-251.
[10] H. Wang, Y. Peng, Y. Liu, X. Li, A. Gu, H. He, M. Feng, D. Mao, L. Guo. Expression of HIWI in endometrial carcinoma tissues and its clinical significance[J]. European Journal of Gynaecological Oncology, 2020, 41(2): 256-259.
[11] A. R. H. Ahmed, R. A. Bakheet, W. Abdelmohsen, M. Mohammed, M. A. Adly. Balance of glandular and stromal Bcl2/Bax expression in pre-neoplastic and neoplastic endometrial tissues[J]. European Journal of Gynaecological Oncology, 2020, 41(2): 265-272.
[12] Y. S. Lee, J. M. Baek, E. K. Park, C. J. Kim, H. J. Lee, J. O. Kim. Expression and therapeutic potential of macrophage migration inhibitory factor and CD74 in ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 65-69.
[13] M.H. Hajeer, A. Al Khader, N.A. Shahin, M.S. Bata. Negative p53 expression and negative high risk HPV in a 26-year-old lady with vulvar keratinizing squamous cell carcinoma: report of a case[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 130-133.
[14] R. Tasaka, Y. Hashiguchi, M. Kasai, T. Fukuda, T. Ichimura, T. Yasui, T. Sumi. Secondary small cell carcinoma of the endometrium after concurrent chemoradiotherapy for cervical cancer: a rare case[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 142-144.
[15] N. K. Šuster, M. Meznaric, N. Škorja, I. Virant-Klun, I. Verdenik, Š. Smrkolj. Cancer stem cell-related marker NANOG expression in ovarian serous tumors using Western blotting and immunohistochemistry: comparison of two techniques[J]. European Journal of Gynaecological Oncology, 2019, 40(6): 948-952.
No Suggested Reading articles found!